Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus PRALATREXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus PRALATREXATE.
ARRANON vs PRALATREXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
Folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase (DHFR), disrupting DNA synthesis and cell proliferation.
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
30 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
Clinical Note
moderatePralatrexate + Digoxin
"Pralatrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePralatrexate + Digitoxin
"Pralatrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePralatrexate + Deslanoside
"Pralatrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePralatrexate + Acetyldigitoxin
"Pralatrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 12–19 hours in patients with normal renal function, supporting a weekly dosing interval.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Renal excretion accounts for approximately 70-80% of the administered dose as unchanged drug; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Antineoplastic
Antineoplastic